Literature DB >> 11060779

Artemisinin drugs: novel antimalarial agents.

R N Price1.   

Abstract

Artemisinin and its derivatives, artesunate and artemether, represent a new class of antimicrobial drug with potent activity against Plasmodium falciparum. Although they show excellent efficacy in both severe and uncomplicated malaria, dosage regimens still need to be optimised and pharmacokinetic profiles defined. In the treatment of uncomplicated malaria, the artemisinin drugs should be used in combination with a long acting antimalarial to protect both drugs against the emergence of resistance. In the treatment of severe malaria, parenteral artemether is at least as effective as quinine and is simpler to use. The use of rectal preparations of artesunate and artemisinin at the rural health level will facilitate early initiation of the treatment of falciparum malaria and this may reduce the proportion of patients progressing to severe disease. All of the artemisinin drugs have comparable efficacy; the choice of derivative should be based upon availability, cost and quality of the preparation. Artemisinin, artesunate and artemether are well-tolerated in both adults and children, with no evidence to date of serious clinical toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060779     DOI: 10.1517/13543784.9.8.1815

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  25 in total

1.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

2.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.

Authors:  Toufigh Gordi; Rujia Xie; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

3.  Artesunate protects pancreatic beta cells against cytokine-induced damage via SIRT1 inhibiting NF-κB activation.

Authors:  L Yu; J F Chen; X Shuai; Y Xu; Y Ding; J Zhang; W Yang; X Liang; D Su; C Yan
Journal:  J Endocrinol Invest       Date:  2015-06-11       Impact factor: 4.256

4.  Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Chu Xuan Anh; Nguyen Xuan Thanh; Bui Dai; Geoffrey W Birrell; Marina Chavchich; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

5.  Expression and characterization of lactate dehydrogenase from Schistosoma japonicum.

Authors:  Gang Lu; Xuchu Hu; Zhaiyu Peng; Hongyan Xie; Yanwen Li; Zhongdao Wu; Xinbing Yu
Journal:  Parasitol Res       Date:  2006-05-11       Impact factor: 2.289

6.  Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism.

Authors:  Vinay Choubey; Pallab Maity; Mithu Guha; Sanjay Kumar; Kumkum Srivastava; Sunil Kumar Puri; Uday Bandyopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

7.  Artemisinin effectiveness in erythrocytes is reduced by heme and heme-containing proteins.

Authors:  Napawan Ponmee; Tatsanee Chuchue; Prapon Wilairat; Yongyuth Yuthavong; Sumalee Kamchonwongpaisan
Journal:  Biochem Pharmacol       Date:  2007-03-15       Impact factor: 5.858

8.  Selection and reversal of Plasmodium berghei resistance in the mouse model following repeated high doses of artemether.

Authors:  Shu-Hua Xiao; Jun-Min Yao; Jürg Utzinger; Yue Cai; Jacques Chollet; Marcel Tanner
Journal:  Parasitol Res       Date:  2003-12-16       Impact factor: 2.289

9.  Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.

Authors:  Gilbert Lefèvre; Polly Carpenter; Claire Souppart; Heinz Schmidli; Mark McClean; Daria Stypinski
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

10.  Towards optimal design of anti-malarial pharmacokinetic studies.

Authors:  Julie A Simpson; Kris M Jamsen; Ric N Price; Nicholas J White; Niklas Lindegardh; Joel Tarning; Stephen B Duffull
Journal:  Malar J       Date:  2009-08-06       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.